Combined early dynamic 18F-FDG PET/CT and conventional whole-body 18F-FDG PET/CT provide one-stop imaging for detecting hepatocellular carcinoma

Clinics and Research in Hepatology and Gastroenterology

Volumn 39, Issue 3, 2015, Pages 324-330

  Wang, Shao Bo ^a,b   Wu, Hu Bing ^a   Wang, Quan Shi ^a   Zhou, Wen Lan ^a   Tian, Ying ^a   Li, Hong Sheng ^a   Ji, Yun Hai ^b   Lv, Liang ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b First People's Hospital of Yunnan Province   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; SILVER; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BOLUS INJECTION; CANCER DIAGNOSIS; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; EARLY DYNAMIC COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMAGE RECONSTRUCTION; LIVER; LIVER CELL CARCINOMA; MALE; PET-CT SCANNER; PILOT STUDY; PROSPECTIVE STUDY; TUMOR DIFFERENTIATION; WHOLE BODY CT; WHOLE BODY PET; WHOLE BODY SCANNER; CARCINOMA, HEPATOCELLULAR; COMPUTER ASSISTED TOMOGRAPHY; LIVER NEOPLASMS; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; WHOLE BODY IMAGING;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 84930858884     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2014.10.010     Document Type: Article

References (23)

1. Ding J., Wang H. Multiple interactive factors in hepatocarcinogenesis. Cancer Lett 2014, 346:17-23.
2. Chen W.Q., Zheng R.S., Zhang S.W. Liver cancer incidence and mortality in China, 2009. Chin J Cancer 2013, 32:162-169.
3. Hwang K.H., Choi D.J., Lee S.Y., Lee M.K., Choe W. Evaluation of patients with hepatocellular carcinomas using [(11)C] acetate and [(18)F] FDG PET/CT: a preliminary study. Appl Radiat Isot 2009, 67:1195-1198.
4. Talbot J.N., Gutman F., Fartoux L., Grange J.D., Ganne N., Kerrou K., et al. PET/CT in patients with hepatocellular carcinoma using [(18)F] fluorocholine: preliminary comparison with [(18)F] FDG PET/CT. Eur J Nucl Med Mol Imaging 2006, 33:1285-1289.
5. Wu H.B., Wang Q.S., Li B.Y., Li H.S., Zhou W.L., Wang Q.Y. F-18 FDG in conjunction with 11C-choline PET/CT in the diagnosis of hepatocellular carcinoma. Clin Nucl Med 2011, 36:1092-1097.
6. Sacks A., Peller P.J., Surasi D.S., Chatburn L., Mercier G., Subramaniam R.M. Value of PET/CT in the management of primary hepatobiliary tumors, part 2. AJR Am J Roentgenol 2011, 197.
7. Shiomi S., Kawabe J. Clinical applications of positron emission tomography in hepatic tumors. Hepatol Res 2011, 41:611-617.
8. Larsson P., Arvidsson D., Bjornstedt M., Isaksson B., Jersenius U., Motarjemi H., et al. Adding 11C-acetate to 18F-FDG at PET examination has an incremental value in the diagnosis of hepatocellular carcinoma. Mol Imaging Radionucl Ther 2012, 21:6-12.
9. Park J.W., Kim J.H., Kim S.K., Kang K.W., Park K.W., Choi J.I., et al. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med 2008, 49:1912-1921.
10. Treglia G., Giovannini E., Di Franco D., Calcagni M.L., Rufini V., Picchio M., et al. The role of positron emission tomography using carbon-11 and fluorine-18 choline in tumors other than prostate cancer: a systematic review. Ann Nucl Med 2012, 26:451-461.
11. Talbot J.N., Fartoux L., Balogova S., Nataf V., Kerrou K., Gutman F., et al. Detection of hepatocellular carcinoma with PET/CT: a prospective comparison of 18F-fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease. J Nucl Med 2010, 51:1699-1706.
12. Bernstine H., Braun M., Yefremov N., Lamash Y., Carmi R., Stern D., et al. FDG PET/CT early dynamic blood flow and late standardized uptake value determination in hepatocellular carcinoma. Radiology 2011, 260:503-510.
13. Schierz J.H., Opfermann T., Steenbeck J., Lopatta E., Settmacher U., Stallmach A., et al. Early dynamic 18F-FDG PET to detect hyperperfusion in hepatocellular carcinoma liver lesions. J Nucl Med 2013, 54:848-854.
14. Bruix J., Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011, 53:1020-1022.
15. Bruix J., Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
16. Murakami T., Kim T., Takamura M., Hori M., Takahashi S., Federle M.P., et al. Hypervascular hepatocellular carcinoma: detection with double arterial phase multi-detector row helical CT. Radiology 2001, 218:763-767.
17. Bolog N., Andreisek G., Oancea I., Mangrau A. CT and MR imaging of hepatocellular carcinoma. J Gastrointestin Liver Dis 2011, 20:181-189.
18. Liu Y.I., Shin L.K., Jeffrey R.B., Kamaya A. Quantitatively defining washout in hepatocellular carcinoma. AJR Am J Roentgenol 2013, 200:84-89.
19. Thomas M.B., Jaffe D., Choti M.M., Belghiti J., Curley S., Fong Y., et al. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 2010, 28:3994-4005.
20. Colli A., Fraquelli M., Casazza G., Massironi S., Colucci A., Conte D., et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 2006, 101:513-523.
21. Tan C.H., Thng C.H., Low A.S., Tan V.K., Hartono S., Koh T.S., et al. Wash-out of hepatocellular carcinoma: quantitative region of interest analysis on CT. Ann Acad Med Singapore 2011, 40:269-275.
22. Ho C.L., Yu S.C., Yeung D.W. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med 2003, 44:213-221.
23. Ahn S.J., Park M.S., Kim K.A., Park J.Y., Kim I., Kang W.J., et al. (1)(8)F-FDG PET metabolic parameters and MRI perfusion and diffusion parameters in hepatocellular carcinoma: a preliminary study. PLoS One 2013, 8.